false
0001314052
0001314052
2026-07-20
2026-07-20
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities
Exchange Act of 1934
Date of Report (Date of earliest event
reported): July 20, 2026
ANAVEX LIFE SCIENCES
CORP.
(Exact name of Registrant as Specified in Its Charter)
| Nevada |
001-37606 |
98-0608404 |
(State or Other Jurisdiction
of Incorporation) |
(Commission File Number) |
(IRS Employer
Identification No.) |
| |
|
|
|
|
630 5th Avenue, 20th Floor
New York, NY USA |
|
10111 |
| (Address of Principal Executive Offices) |
|
(Zip Code) |
Registrant’s Telephone Number,
Including Area Code: 1-844-689-3939
Check the appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following provisions:
☐ Written communications pursuant to Rule 425 under the
Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant
to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications
pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class |
|
Trading Symbol(s) |
|
Name of each exchange on which registered |
| Common Stock, par value $0.001 per share |
|
AVXL |
|
Nasdaq Stock Market LLC |
Indicate by check mark whether the registrant is an emerging growth company
as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act
of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant
to Section 13(a) of the Exchange Act. ☐
On July 20, 2026, Anavex Life Sciences Corp. (the “Company”)
timely submitted its plan (the “Compliance Plan”) to the Listing Qualifications Department (the “Nasdaq Staff”)
of The Nasdaq Stock Market LLC to regain compliance with Nasdaq Listing Rule 5250(c)(1), which requires listed companies to timely file
all required periodic financial reports with the Securities and Exchange Commission (“Rule 5250(c)(1)”). As previously disclosed,
on May 20, 2026, the Company received a deficiency notification letter (the “Notice”) from the Nasdaq Staff indicating that,
as a result of the Company’s inability to timely file its Quarterly Report on Form 10-Q for the quarterly period ended March 31,
2026, it is not in compliance with Rule 5250(c)(1).
The Notice has no immediate effect on the listing of the Company’s
common stock, which continues to trade on The Nasdaq Global Select Market under the symbol “AVXL”.
The Compliance Plan is currently under review by the Nasdaq Staff. If the
Compliance Plan is accepted by the Nasdaq Staff, the Nasdaq Staff may grant an extension for the Company to regain compliance. If the
Compliance Plan is not accepted by the Nasdaq Staff, the Company will have an opportunity to request a hearing on the Nasdaq Staff’s
determination before an independent Hearings Panel.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| |
|
ANAVEX LIFE SCIENCES CORP. |
| |
|
|
|
| Date: |
July 20, 2026 |
By: |
/s/ Sandra Boenisch |
| |
|
|
Sandra Boenisch, CPA, CGA
Principal Financial Officer, Treasurer |
